Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Skip to content
Home / News / Civilizational diseases / The American Heart Association (AHA) has officially defined what they call the Cardiorenal Metabolic Syndrome (CKM) for the first time

The American Heart Association (AHA) has officially defined what they call the Cardiorenal Metabolic Syndrome (CKM) for the first time

Stage 0: At this stage, there are no risk factors for CKM, and the goal is to prevent CKM syndrome (incredibly unhealthy weight gain) by achieving and maintaining a healthy lifestyle.

Stage 1: At this stage, there is overweight, abdominal obesity, or fat tissue dysfunction (clinically manifested by impaired glucose tolerance or a prediabetic state) without other metabolic risk factors for cardiovascular diseases (CVD).

Stage 2: At this stage, metabolic risk factors are present (hypertriglyceridemia, hypertension, metabolic syndrome, diabetes) and kidney diseases. The goal is to manage risk factors to prevent progression to CVD and kidney failure.

Stage 3: This stage describes individuals with subclinical CVD with metabolic risk factors or kidney disease or those at high predicted risk of CVD.

Stage 4: Individuals with CKM syndrome at stage 4 have symptomatic CVD, excess fat tissue, metabolic risk factors, or kidney disease.

Based on: https://doi.org/10.1161/CIR.0000000000001184